Clinical Trial Update: Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety, biodistribution, radiation dosimetry, and imaging protocol optimization of GEH120714 (18F) injection in healthy volunteers an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GEH120714 (18F) injection (GEH120714)

Snippet

Sponsor: GE Healthcare | Conditions: Relapsing-remitting Multiple Sclerosis (rrMS) | Phase 1 | Status: COMPLETED